Genetic Obesity Drugs Comprehensive Study by Type (Monogenic, Syndromic), Category (Class 1: BMI - 30 to < 35, Class 2: BMI - 35 to < 40, Class 3: BMI - > 40), Drug (Bupropion-naltrexone, Liraglutide, Orlistat, Phentermine-topiramate, Others), Distribution Channel (Hospitals pharmacy, Retail Pharmacy, Drug Stores, Online Pharmacy), End-User (Hospitals, Clinics, Diagnostic Centres, Government) Players and Region - Global Market Outlook to 2030

{reportSlug=global-genetic-obesity-drugs-market, reportId=185213, mktKeyword=Genetic Obesity Drugs, cagr=9.00, publishDate=Feb 2024, priceOption2=6800, reportTitle=Genetic Obesity Drugs Comprehensive Study by Type (Monogenic, Syndromic), Category (Class 1: BMI - 30 to < 35, Class 2: BMI - 35 to < 40, Class 3: BMI - > 40), Drug (Bupropion-naltrexone, Liraglutide, Orlistat, Phentermine-topiramate, Others), Distribution Channel (Hospitals pharmacy, Retail Pharmacy, Drug Stores, Online Pharmacy), End-User (Hospitals, Clinics, Diagnostic Centres, Government) Players and Region - Global Market Outlook to 2030, baseYr=2023, totalTableFig=218, priceOption1=3750, forecastYr=2030, noOfPages=240, reportKey=184712, breadcrum=Global Genetic Obesity Drugs Market}